Check out your Company Bowl for anonymous work chats.
For the full year 2025, Galderma delivered record net sales of 5,207 million USD, exceeding 5 billion USD for the first year. Year-on-year net sales growth for the year was 17.7% at constant currency. Growth overall was predominantly volume-driven, with a favorable product mix more than offsetting pricing effects from the competitive environment.
Galderma has announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026. Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization.
S&P Global Ratings (S&P) has assigned Galderma a ‘BBB’ long-term issuer credit rating with a positive outlook. The rating reflects Galderma’s strong track record of growth and its leading positions across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. S&P notes the company’s well-established brand portfolio, global footprint, including an expanding presence in emerging markets, and continued investment in science-based innovation.
Galderma announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake. Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership in dermatology and L’Oréal’s expertise as the world’s leading beauty player.
Galderma announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. Results showed that Nemluvio maintained long-term disease control and a well-tolerated safety profile, with clinically meaningful improvements in itch intensity, skin lesions and quality of life up to three years.
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane® syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands. These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and our commitment to continuing to drive innovation in the field.
We are pleased to announce the opening of Galderma’s new Global Capability Center (GCC) in Kraków, Poland. This strategic addition to our global footprint brings a deeper IT-led specialization, further strengthening our technology capabilities, including AI, and supporting our continued growth. Our teams are expected to move into the Kraków GCC by Q3 2026, and we plan to gradually expand our presence in the region over the coming years.
Galderma has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT‑based hyaluronic acid injectables ever authorized in Japan. The products – designed for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds – are now commercially available in the market. These launches mark a major milestone for Galderma and represent an important chapter in its JPAC growth strategy, supporting the company’s continuing expansion in one of the region’s most dynamic aesthetics markets.
Galderma has announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process.
Galderma has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin. Galderma will leverage its expertise in dermatology to advance awareness, understanding, education, and treatment approaches for menopause-related skin changes. With around 85% of aesthetic patients being female, it is important to understand how these treatments can support women at all stages of life, especially during the complex time of the menopause. To help advance this understanding, Galderma has made the pioneering decision to now include menopausal status in its clinical trials to provide critical insights into how its injectable aesthetic treatments can best serve this patient population.
